[
  {
    "ts": null,
    "headline": "Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)",
    "summary": "Learn why Summit Therapeutics' stock soared 888% on positive Phase 3 data for ivonescimab, with a potential value of $20.5B-$29B. Read more here.",
    "url": "https://finnhub.io/api/news?id=122b00e20de0960a706e639d21f8fa7878fccc10841fbf89c3f6e119cbc4ba0d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737192780,
      "headline": "Summit Therapeutics: Data Signals A Potential Paradigm Shift In NSCLC (Rating Upgrade)",
      "id": 132420238,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352063892/image_1352063892.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Learn why Summit Therapeutics' stock soared 888% on positive Phase 3 data for ivonescimab, with a potential value of $20.5B-$29B. Read more here.",
      "url": "https://finnhub.io/api/news?id=122b00e20de0960a706e639d21f8fa7878fccc10841fbf89c3f6e119cbc4ba0d"
    }
  }
]